Literature DB >> 33049161

Engineering the Microbiome to Prevent Adverse Events: Challenges and Opportunities.

Saad Khan1, Ruth Hauptman1, Libusha Kelly1,2.   

Abstract

In the past decade of microbiome research, we have learned about numerous adverse interactions between the microbiome and medical interventions such as drugs, radiation, and surgery. What if we could alter our microbiomes to prevent these events? In this review, we discuss potential routes to mitigate microbiome adverse events, including applications from the emerging field of microbiome engineering. We highlight cases where the microbiome acts directly on a treatment, such as via differential drug metabolism, and cases where a treatment directly harms the microbiome, such as in radiation therapy. Understanding and preventing microbiome adverse events is a difficult challenge that will require a data-driven approach involving causal statistics, multiomics techniques, and a personalized means of mitigating adverse events. We propose research considerations to encourage productive work in preventing microbiome adverse events, and we highlight the many challenges and opportunities that await.

Entities:  

Keywords:  adverse drug response; causal inference; metagenomics; microbiome adverse event; microbiome engineering; personalized medicine

Mesh:

Substances:

Year:  2020        PMID: 33049161      PMCID: PMC9015100          DOI: 10.1146/annurev-pharmtox-031620-031509

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   16.459


  118 in total

Review 1.  Probiotics, prebiotics, and synbiotics--approaching a definition.

Authors:  J Schrezenmeir; M de Vrese
Journal:  Am J Clin Nutr       Date:  2001-02       Impact factor: 7.045

2.  Pharmacological inhibition of bacterial β-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo.

Authors:  Kai-Wen Cheng; Chih-Hua Tseng; Cherng-Chyi Tzeng; Yu-Lin Leu; Ta-Chun Cheng; Jaw-Yuan Wang; Jia-Ming Chang; Yun-Chi Lu; Chiu-Min Cheng; I-Ju Chen; Yi-An Cheng; Yeh-Long Chen; Tian-Lu Cheng
Journal:  Pharmacol Res       Date:  2018-11-01       Impact factor: 7.658

Review 3.  The gastrointestinal microbiota as a site for the biotransformation of drugs.

Authors:  Tiago Sousa; Ronnie Paterson; Vanessa Moore; Anders Carlsson; Bertil Abrahamsson; Abdul W Basit
Journal:  Int J Pharm       Date:  2008-07-16       Impact factor: 5.875

Review 4.  Novel insight into the role of microbiota in colorectal surgery.

Authors:  Radu Bachmann; Daniel Leonard; Nathalie Delzenne; Alex Kartheuser; Patrice D Cani
Journal:  Gut       Date:  2017-02-02       Impact factor: 23.059

5.  Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial.

Authors:  Dina Kao; Brandi Roach; Marisela Silva; Paul Beck; Kevin Rioux; Gilaad G Kaplan; Hsiu-Ju Chang; Stephanie Coward; Karen J Goodman; Huiping Xu; Karen Madsen; Andrew Mason; Gane Ka-Shu Wong; Juan Jovel; Jordan Patterson; Thomas Louie
Journal:  JAMA       Date:  2017-11-28       Impact factor: 56.272

Review 6.  Host and microbiome multi-omics integration: applications and methodologies.

Authors:  Qing Wang; Kaicen Wang; Wenrui Wu; Eleni Giannoulatou; Joshua W K Ho; Lanjuan Li
Journal:  Biophys Rev       Date:  2019-01-09

7.  Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection.

Authors:  Ilan Youngster; George H Russell; Christina Pindar; Tomer Ziv-Baran; Jenny Sauk; Elizabeth L Hohmann
Journal:  JAMA       Date:  2014-11-05       Impact factor: 56.272

Review 8.  Therapeutic significance of β-glucuronidase activity and its inhibitors: A review.

Authors:  Paul Awolade; Nosipho Cele; Nagaraju Kerru; Lalitha Gummidi; Ebenezer Oluwakemi; Parvesh Singh
Journal:  Eur J Med Chem       Date:  2019-12-04       Impact factor: 6.514

9.  An Atlas of β-Glucuronidases in the Human Intestinal Microbiome.

Authors:  Rebecca M Pollet; Emma H D'Agostino; William G Walton; Yongmei Xu; Michael S Little; Kristen A Biernat; Samuel J Pellock; Loraine M Patterson; Benjamin C Creekmore; Hanna N Isenberg; Rohini R Bahethi; Aadra P Bhatt; Jian Liu; Raad Z Gharaibeh; Matthew R Redinbo
Journal:  Structure       Date:  2017-06-01       Impact factor: 5.006

10.  Extensive impact of non-antibiotic drugs on human gut bacteria.

Authors:  Lisa Maier; Mihaela Pruteanu; Michael Kuhn; Georg Zeller; Anja Telzerow; Exene Erin Anderson; Ana Rita Brochado; Keith Conrad Fernandez; Hitomi Dose; Hirotada Mori; Kiran Raosaheb Patil; Peer Bork; Athanasios Typas
Journal:  Nature       Date:  2018-03-19       Impact factor: 49.962

View more
  4 in total

Review 1.  Gut Microbiome and Common Variable Immunodeficiency: Few Certainties and Many Outstanding Questions.

Authors:  Gilda Varricchi; Remo Poto; Gianluca Ianiro; Alessandra Punziano; Gianni Marone; Antonio Gasbarrini; Giuseppe Spadaro
Journal:  Front Immunol       Date:  2021-08-02       Impact factor: 7.561

2.  Closely related Salmonella Derby strains triggered distinct gut microbiota alteration.

Authors:  Xiaohui Yuan; Han Xue; Xiaomeng Xu; Xinan Jiao; Zhiming Pan; Yunzeng Zhang
Journal:  Gut Pathog       Date:  2022-01-25       Impact factor: 4.181

Review 3.  Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy.

Authors:  Zhujiang Dai; Jihong Fu; Xiang Peng; Dong Tang; Jinglue Song
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

4.  Machine Learning Predicts Drug Metabolism and Bioaccumulation by Intestinal Microbiota.

Authors:  Laura E McCoubrey; Stavriani Thomaidou; Moe Elbadawi; Simon Gaisford; Mine Orlu; Abdul W Basit
Journal:  Pharmaceutics       Date:  2021-11-25       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.